We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Koj6.0
Kojic Acid Research
Mostly mechanism / observationalModerate safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Kojic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 1995–2023 with a typical study size of 50 participants.
Based on 7 studies · 1 meta-analysis · 3 RCTs · 435 total participants
Confidence
Moderate
By outcome
Skin tone & pigmentationModest reduction in melasma/hyperpigmentation, strongest when combined with other brighteners (cosmetic, not a health outcome) · 8-12 weeks
Mostly mechanism / observational6 studies
Steady research
1 study in the last 5 years · Latest meta-analysis: 2023
199520092023
1Meta-Analysis2023
Hydroquinone (HQ) monotherapy (SMD -1.3, 95% CI [-1.6 to -1.0]), HQ-containing combination therapy (-1.4, [-1.7 to -1.1]), cysteamine (-1.6, [-2.0 to -1.2]), tranexamic acid (-1.5, [-2.0 to -1.1]), azelaic acid (-1.3, [-1.7 to -1.0]), and kojic acid (-0.9, [-1.3 to -0.5]) demonstrated comparable efficacy, while zinc sulfate did not exhibit statistically significant improvement (-1.2, [-2.7 to 0.4]).
Chang YF, Lee TL, Oyerinde O, Desai SR, Aljabban A, Bay CP, Bain PA, Chung HJ. · J Cosmet Dermatol (2023)
Pooled 45 efficacy studies (2359 patients) of topical melasma treatments using MASI standardised mean differences
Kojic acid produced a statistically significant but numerically smaller MASI reduction (SMD -0.9) than hydroquinone, cysteamine, tranexamic acid, and azelaic acid — among the weaker effect sizes
Kojic acid had a low skin-irritation incidence (5.3%), well below HQ-containing combinations (50.9%)
More than half of the melasma cleared in 24/40 (60%) patients receiving kojic acid compared to 19/40 (47.5%) patients receiving the gel without kojic acid.
Lim JT. · Dermatol Surg (1999)
Split-face randomized design in 40 women with epidermal melasma: 2% kojic acid added to a 10% glycolic acid + 2% hydroquinone base vs the base alone
The kojic-acid side cleared more melasma (60% vs 47.5% achieving >50% clearance), and the only complete clearances occurred on that side
Benefit is incremental on top of an active hydroquinone/glycolic base, not standalone kojic acid efficacy
Kojic acid in synergy with hydroquinone is a superior depigmenting agent as compared with other combinations.
Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. · Indian J Dermatol (2013)
80 melasma patients randomized over 12 weeks to kojic acid 1% alone, kojic acid + hydroquinone 2%, kojic acid + betamethasone, or all three (MASI-assessed)
Kojic acid combined with hydroquinone was the most effective; kojic acid monotherapy performed below the hydroquinone combinations
Directly shows kojic acid's benefit is largely realised in combination rather than standalone
Trichloroacetic acid 20% showed better results than Jessner's solution as peeling agent and hydroquinone 2% with kojic acid as a topical agent in the treatment of melasma.
Azzam OA, Leheta TM, Nagui NA, Shaarawy E, Hay RM, Hilal RF. · J Cosmet Dermatol (2009)
45 melasma patients randomized to Jessner's peel, 20% TCA peel, or topical hydroquinone 2% + kojic acid over 16 weeks (MASI)
The topical hydroquinone + kojic acid arm reduced MASI but performed significantly worse than both chemical-peel arms (P=0.01 vs Jessner's; P<0.001 vs TCA)
Comparative counter-evidence: even in combination, topical kojic acid underperformed procedural peels
Biochemical human-tyrosinase assay plus MelanoDerm artificial-skin model comparing hydroquinone, arbutin, kojic acid, and 4-n-butylresorcinol
Confirms kojic acid's tyrosinase-inhibition mechanism (IC50 ~500 μmol/L), ~10x more potent than arbutin/hydroquinone biochemically but far weaker than 4-n-butylresorcinol
In artificial skin, kojic acid inhibited melanin only at IC50 >400 μmol/L — modest tissue-level potency, contextualizing its limited clinical effect
A 20% azelaic acid formulation and another one containing 5% ascorbyl glucosamine, 1% kojic acid and alpha-hydroxyacid esters appeared inefficacious on solar lentigines.
Kojic acid is considered to have high sensitizing potential, as a comparatively high frequency of contact sensitivity was observed in patients using products containing it (5 out of 8).
Nakagawa M, Kawai K, Kawai K. · Contact Dermatitis (1995)
Patch-tested 220 women with suspected cosmetic-related contact dermatitis over one year
Of the 8 who had used kojic-acid products, 5 reacted to kojic acid and their own products; all 212 never-exposed patients tested negative
Sensitised patients developed facial dermatitis 1-12 months after starting use — a real, latency-delayed safety risk